# Fractyl Health Meets Six-Month Primary Endpoint in Pivotal Revita Weight Study

- URL: https://stocks.freetheai.org/news/fractyl-health-meets-six-month-primary-endpoint-in-pivotal-revita-weight-study-cd4518
- Published: 2026-10-16T11:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:GUTS](https://stocks.freetheai.org/symbols/NASDAQ-GUTS)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Fractyl Health, Inc. (GUTS) reported that its pivotal REMAIN-1 study met its six-month co-primary endpoint. The trial evaluated the company's Revita procedural therapy against a sham procedure for maintaining weight loss after GLP-1 medication. Results demonstrated a statistically significant reduction in weight regain for patients receiving Revita, with 80% of initial weight loss retained compared to 67% in the control group. Additionally, 32% of Revita patients maintained stable weight or lost more weight, compared with 18% in the sham group, and no procedure- or device-related serious adverse events were observed.

The trial results indicate that the Revita system may offer a durable non-drug alternative to help individuals retain body weight reduction after stopping or reducing weight-loss drugs. The data also highlighted a clear dose-response relationship, as participants receiving full ablation experienced 53% less weight regain than the control group. Showing a favorable safety record alongside statistically significant efficacy strengthens the therapeutic rationale for post-GLP-1 maintenance therapy.

Looking ahead, Fractyl Health plans to submit a De Novo application to the U.S. Food and Drug Administration in the fourth quarter of 2026. Investors and clinicians will also look for 12-month trial outcomes expected in the first quarter of 2027 to confirm long-term efficacy and safety ahead of potential market entrance.

## Key points

- Fractyl Health met its six-month co-primary endpoint in the pivotal REMAIN-1 study testing its Revita device.
- Patients receiving Revita retained 80% of weight loss compared to 67% in the sham group.
- Patients undergoing full ablation experienced 53% less weight regain than the control group.
- No serious adverse events related to the device or procedure were reported during the trial.
- Fractyl Health plans a De Novo FDA submission in late Q4 2026, with 12-month data expected in Q1 2027.

## Questions and answers

### What were the key results of Fractyl Health's REMAIN-1 study?

The study met its six-month endpoint, showing patients treated with Revita retained 80% of weight loss versus 67% for sham control. Additionally, 32% of Revita patients maintained or lost further weight, compared to 18% in the control group.

### When will Fractyl Health submit Revita for FDA approval?

Fractyl Health plans to submit a De Novo application to the FDA in late Q4 2026. The company also expects to report 12-month trial data in Q1 2027.

### Were there any safety concerns reported in the Revita trial?

No device-related or procedure-related serious adverse events were reported in the six-month readout of the REMAIN-1 trial.